Q-omics provides the consensus-scored LINC01550 profile across patient tissues and cancer cell-line models. LINC01550 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01550 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, LINC01550 RNA expression shows 15,693 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where LINC01550 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01550 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01550 survival associations across molecular data types. LINC01550 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01550 RNA expression–survival associations across cancer types. High LINC01550 expression shows favorable associations in KIRC, MESO, UVM, COAD, KIRP and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01550 RNA expression.
This table summarizes LINC01550 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01550. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01550 shows lower tumor expression in KICH, THCA, BLCA, UCEC and BRCA and higher tumor expression in KIRC. The KICH box plot shows higher LINC01550 RNA expression in normal versus tumor tissue (log2 FC = −1.831, t-test p < 0.001).
This table shows molecular features associated with LINC01550 in patient tissues and cancer cell lines. In patient samples, LINC01550 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01550 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
